METHODS OF DETERMINING ANTIBIOTIC RESISTANCE

• US 20090317804A1
• Filed: 05/14/2008
• Published: 12/24/2009
• Est. Priority Date: 02/19/2008
• Status: Abandoned Application

• Current Assignee: OpGen Inc.
• Original Assignee: OpGen Inc.
• Inventors: BRISKA, Adam M.
• Application Number:
  US12/120,592
• Publication Number:
  US 20090317804A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/683 involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
• CPC Class Codes: C12Q 2563/107 fluorescence
• CPC Class Codes: C12Q 2565/518 characterised by the immobilisation of the nucleic acid sample or target
• CPC Class Codes: C12Q 2565/601 being a microscope, e.g. atomic force microscopy [AFM]
• CPC Class Codes: G16B 30/00 ICT specially adapted for sequence analysis involving nucleotides or amino acids
• CPC Class Codes: G16B 30/10 Sequence alignment; Homology search
• CPC Class Codes: G16B 50/00 ICT programming tools or database systems specially adapted for bioinformatics
• CPC Class Codes: Y02A 90/10 Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

This disclosure relates to methods of determining an antibiotic resistance profile of a bacterium, and methods of treating a patient with a therapeutically effective antibiotic. The methods include comparing the restriction map of the nucleic acid with a restriction map database, and determining antibiotic resistance of the bacterium by matching regions of the nucleic acid to corresponding regions in the database.

Claims

1. A method of determining antibiotic resistance, the method comprising the steps of:

(a) obtaining nucleic acid from a bacterium;

(b) imaging the nucleic acid;

(c) obtaining a restriction map of the nucleic acid;

(d) comparing the restriction map of the nucleic acid with a restriction map database; and

(e) determining antibiotic resistance of the bacterium by matching regions of said nucleic acid to corresponding regions in said database.

2. The method of claim 1, further comprising the step of linearizing said nucleic acid.

3. The method of claim 1, wherein the bacterium is at least one species selected from the group consisting of E. coli and S. aureus.

4. The method according to claim 3, wherein the S. aureus is a community-acquired methicillin-resistant strain of S. aureus.

5. The method according to claim 3, wherein the S. aureus is a hospital-acquired methicillin-resistant strain of S. aureus.

6. The method of claim 1, wherein the nucleic acid comprises substantially all genomic DNA of the bacterium.

7. The method of claim 1, wherein the nucleic acid comprises a transcriptome of the bacterium.

8. The method of claim 1, wherein the nucleic acid is deoxyribonucleic acid.

9. The method of claim 1, wherein the nucleic acid is ribonucleic acid.

10. The method of claim 1, further comprising digesting the nucleic acid with one or more enzymes prior to the imaging step.

11. The method of claim 10, wherein the enzymes are selected from the group consisting of:

BglII, NcoI, XbaI, and BamHI.

12. The method of claim 1, wherein the imaging step comprises labeling the nucleic acid.

13. The method of claim 1, wherein the antibiotic is at least one selected from the group consisting of:

methicillin, oxacillin, ciproflaxin, erythromycin, tetracyclin, clindamycin, trimethoprim/sulfa, vancomycin, penicillin G, levofloxacin, moxyfloxacin, rifampicin, linezolid, quinupristin/dalfopristin, gentamycin, and nitrofurantoin.

14. The method of claim 1, wherein the restriction database comprises a restriction map similarity cluster.

15. The method of claim 1, wherein the restriction database comprises a restriction map from at least one member of the clade of the organism.

16. The method of claim 1, wherein the restriction database comprises a restriction map from at least one subspecies of the organism.

18. The method of claim 1, wherein the database comprises a restriction map comprising motifs common to a genus, a species, a strain, a sub-strain, or an isolate of the organism.

19. The method of claim 18, wherein said motif is a mec cassette.

20. A method of determining an antibiotic resistance profile of a bacterium, the method comprising the steps of:

obtaining nucleic acid from a bacterium;

preparing an optical map of said nucleic acid;

identifying at least one motif present in said nucleic acid that is indicative of bacterial resistance; and

correlating said at least one motif with resistance to one or more antibiotics, thereby to determine the antibiotic resistance profile for said bacterium.

21. The method of claim 20, wherein said preparing step comprises linearizing said nucleic acid, digesting said nucleic acid with one or more restriction enzymes, and labeling said nucleic acid for imaging.

22. The method of claim 20, wherein said motif is selected from the group consisting of a mec cassette and psiSA2 prophage.

23. A method of determining a therapeutically effective antibiotic for treating a subject, the method comprising:

(a) obtaining a sample from a patient, wherein the sample is suspected to contain an infectious organism;

(b) obtaining a nucleic acid from the organism;

(b) preparing an optical map of said nucleic acid

(d) determining an antibiotic resistance profile of said organism by comparing said optical map with at least one database containing antibiotic resistance data; and

(e) selecting a therapeutically effective antibiotic for treating said patient.

17. The method of claim 31, wherein the restriction database comprises a restriction map from a genus, a species, a strain, a sub-strain, or an isolate of the organism.

24. The method of claim 23, further comprising the step of identifying said organism.

25. The method of claim 23, wherein the sample is selected from the group consisting of food, human tissue, body fluid, air, water, soil, plant material, and unknown material.

26. The method of claim 25, wherein the body fluid is selected from the group consisting of blood, sputum, saliva, urine, drainage from a body part, and drainage from an abscess.

27. The method of claim 23, wherein the organism is at least one type selected from the group consisting of a microorganism, a bacterium, a virus, and a fungus.

28. The method of claim 27, wherein the bacterium is at least one species selected from the group consisting of E. coli and S. aureus.

29. The method according to claim 28, wherein the S. aureus is a community-acquired methicillin-resistant strain of S. aureus.

30. The method according to claim 28, wherein the S. aureus is a hospital-acquired methicillin-resistant strain of S. aureus.

31. The method of claim 23, wherein said database comprises a restriction map similarity cluster.

32. The method of claim 23, wherein the restriction database comprises a restriction map from at least one member of the clade of the organism.

33. The method of claim 23, wherein the restriction database comprises a restriction map from at least one subspecies of the organism.

34. The method of claim 23, wherein the restriction database comprises a restriction map from a genus, a species, a strain, a sub-strain, or an isolate of the organism.

35. The method of claim 23, wherein the database comprises a restriction map comprising motifs common to a genus, a species, a strain, a sub-strain, or an isolate of the organism.